Corporal Michael J. Crescenz VA Medical Center

Philadelphia, Pennsylvania 19104

4 studies enrolling now · 16 studies all time

What they study most

Alcohol Use Disorder, Alcohol Use Disorder (AUD), Alcoholism, Biliary Tract Cancer, Castrate-sensitive, Castrate-sensitive Prostate Cancer, Cirrhosis, Decompensated Cirrhosis of Liver, End Stage Liver Disease, Hepatitis B, Hepatitis C, Hepatocellular Cancer

Studies at this site

• Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder — Recruiting now
• Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. — Recruiting now
• Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates — Recruiting now
• A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD — Running, not enrolling
• Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease — Starting soon
• Utility of CAML as Diagnostic for Early Stage Lung Cancer — Stopped early
• Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD) — Completed
• ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk — Running, not enrolling
• Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations — Running, not enrolling
• Developing Personalized Medicine Strategies to Increase Physical Activity in Parkinson's Disease (PD) Through Digital Health Technology — Completed
• Parkinson's Disease Inflammatory Biomarker Profiling — Stopped early
• Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC) — Completed
• Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer — Stopped early
• Way to Cure HCV Adherence — Completed
• A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers — Completed
• An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis — Withdrawn before enrolling